Introduction to acivir pills (acyclovir)
Acivir Pills is a brand name for acyclovir, an antiviral medication widely prescribed for herpesvirus infections worldwide. Developed in the 1970s by scientists at Burroughs Wellcome, acyclovir is a landmark in antiviral therapy as one of the first medications to selectively target virus-infected cells. This selectivity is achieved through activation by a viral enzyme, ensuring the drug is primarily active where the virus is replicating. Acivir Pills are available in 200 mg, 400 mg, and 800 mg strengths for flexible dosing. The oral bioavailability of acyclovir is 15-30%, requiring frequent dosing three to five times daily. Acivir Pills are used for genital herpes, orolabial herpes, herpes zoster, and varicella. The drug is also used off-label for other herpesvirus infections. The safety profile is excellent, with nausea, vomiting, diarrhea, and headache being the most common adverse effects. Generic acyclovir is widely available and affordable. From Happy Family Store
Mechanism of action
Acyclovir exerts its antiviral activity through a highly selective, multi-step mechanism that targets herpesvirus DNA replication. The first and most critical step is the activation of acyclovir by viral thymidine kinase (TK), an enzyme encoded by herpes simplex virus and varicella-zoster virus that is expressed only in virus-infected cells. Viral TK phosphorylates acyclovir to acyclovir monophosphate, converting the inactive prodrug into its active form. This step does not occur to any significant extent in uninfected cells, as cellular thymidine kinases have very low affinity for acyclovir. This selectivity is the fundamental basis for the drug’s excellent safety profile, as it is preferentially activated at the site of viral replication. After the initial phosphorylation, cellular enzymes take over. Guanylate kinase phosphorylates acyclovir monophosphate to acyclovir diphosphate, and then various cellular kinases, including phosphoglycerate kinase and creatine kinase, further phosphorylate acyclovir diphosphate to acyclovir triphosphate, the active antiviral moiety. Acyclovir triphosphate accumulates to high concentrations in virus-infected cells, reaching levels 40-100 times higher than those found in uninfected cells, due to both the efficient initial phosphorylation by viral TK and the trapping of the phosphorylated compound within the cell. Acyclovir triphosphate then exerts its antiviral effect through two complementary mechanisms. First, it competitively inhibits viral DNA polymerase, the enzyme responsible for synthesizing new viral DNA. Acyclovir triphosphate binds to the viral DNA polymerase with a much higher affinity than the natural substrate, deoxyguanosine triphosphate, effectively blocking the enzyme’s ability to incorporate normal nucleotides into the growing DNA chain. Second, when acyclovir triphosphate is incorporated into the viral DNA strand despite the competitive inhibition, it causes chain termination. Acyclovir lacks the 3-hydroxyl group that is required for forming the phosphodiester bond with the next nucleotide. Once acyclovir is incorporated at the 3 end of the growing DNA chain, no further nucleotides can be added, and DNA synthesis is irrevocably terminated. The viral DNA polymerase cannot remove the acyclovir molecule efficiently, so the terminated chain remains in place, preventing the completion of viral DNA replication. The selectivity of acyclovir is further enhanced by the differential sensitivity of viral and cellular DNA polymerases to the drug. The concentration of acyclovir triphosphate required to inhibit viral DNA polymerase is 30-100 times lower than that required to inhibit human cellular DNA polymerases. This means that even if a small amount of acyclovir triphosphate accumulates in uninfected cells, it will have minimal effect on normal cellular DNA replication. Acyclovir has its greatest activity against HSV-1, followed by HSV-2, with VZV being somewhat less susceptible. The differences in susceptibility correlate with the efficiency of TK-mediated phosphorylation in different viruses. HSV-1 TK phosphorylates acyclovir most efficiently, while VZV TK is approximately 200 times less efficient. This is why higher doses of acyclovir are required for the treatment of VZV infections compared to HSV infections. The activity of acyclovir against Epstein-Barr virus and cytomegalovirus is limited, as these viruses do not encode a TK enzyme. For EBV, a small amount of phosphorylation can occur through alternative pathways, but the activity is insufficient for most clinical applications. For CMV, acyclovir has minimal activity, and other agents such as ganciclovir and valganciclovir are preferred. The mechanisms of action of acyclovir have been characterized and provide a model for the development of selective antiviral agents. Understanding these mechanisms is essential for optimizing the clinical use of acyclovir, predicting susceptibility patterns, and managing drug resistance.
Therapeutic indications
Acivir Pills are indicated for the treatment of many herpesvirus infections. The most common indication is genital herpes, a sexually transmitted infection caused primarily by HSV-2 and increasingly by HSV-1. For first-episode genital herpes, which typically presents with multiple painful vesicular lesions, fever, and malaise, oral acyclovir 200 mg five times daily or 400 mg three times daily for 7-10 days reduces the duration of viral shedding, accelerates healing, and decreases the formation of new lesions. Early treatment is particularly important for first episodes, as they tend to be more severe and prolonged than recurrences. For recurrent genital herpes, episodic therapy with acyclovir 200 mg five times daily or 400 mg three times daily for 5 days, initiated at the first sign of recurrence (prodromal symptoms such as tingling, burning, or itching), reduces the duration of symptoms by approximately 1-2 days and accelerates healing. Patients who experience frequent recurrences, defined as six or more episodes per year, are candidates for chronic suppressive therapy with acyclovir 400 mg twice daily. Suppressive therapy reduces recurrence rates by 70-80% and improves quality of life, and it can be continued for extended periods with annual reassessment of the recurrence pattern. Orolabial herpes, commonly known as cold sores or fever blisters, is caused primarily by HSV-1 and affects the lips and perioral area. Treatment with oral acyclovir 200 mg five times daily for 5 days, initiated at the first sign of a lesion, reduces the duration of symptoms and the time to healing. The topical cream formulation is also available over the counter for mild cases, but oral therapy is more effective, particularly for more severe or frequent episodes. Herpes zoster, or shingles, is caused by reactivation of latent VZV, typically in older adults or immunocompromised individuals. It presents as a painful, vesicular rash in a dermatomal distribution. Treatment with acyclovir 800 mg five times daily for 7-10 days, initiated within 72 hours of rash onset, reduces the duration of acute pain, accelerates lesion healing, and may reduce the incidence and severity of postherpetic neuralgia, the most common complication of shingles. The high dose required for VZV infections reflects lower sensitivity of VZV to acyclovir compared to HSV. Varicella, or chickenpox, is a primary VZV infection that typically affects children. Treatment with acyclovir 20 mg/kg (up to 800 mg) four times daily for 5 days, initiated within 24 hours of rash onset, reduces the duration and severity of symptoms, including fever and the number of lesions. Acyclovir is particularly recommended for varicella in adolescents, adults, pregnant women, and immunocompromised patients, who are at increased risk for complications such as pneumonia and encephalitis. Prophylactic use of acyclovir is indicated in immunocompromised patients, including hematopoietic stem cell and solid organ transplant recipients, to prevent HSV and VZV reactivation during periods of intensive immunosuppression. Prophylaxis is typically started at the time of transplantation or induction of immunosuppression and continued for several months. In patients with HIV infection, acyclovir is used for the treatment of acute episodes and for suppressive therapy to prevent recurrent HSV infections. Higher doses may be required in advanced HIV disease due to the impaired immune response. The broad range of indications for Acivir Pills reflects central role of acyclovir for herpesvirus infections across diverse patient populations. Each indication requires careful consideration of the appropriate dose, timing of initiation, and duration of therapy to achieve optimal outcomes. Early initiation of therapy is associated with better outcomes for all indications, and patient education about recognizing early symptoms and seeking prompt treatment is an important component of effective management.
Dosage and administration
The dosing of Acivir Pills must be carefully tailored to the specific indication, patient age and weight, and renal function. For adults with normal renal function, the standard dose for first-episode genital herpes is 200 mg five times daily (approximately every 4 hours while awake) or 400 mg three times daily for 7-10 days. For recurrent genital herpes, 200 mg five times daily or 400 mg three times daily for 5 days is recommended. For chronic suppressive therapy of recurrent genital herpes, 400 mg twice daily is the standard regimen. For orolabial herpes, 200 mg five times daily for 5 days is recommended. For herpes zoster in immunocompetent adults, 800 mg five times daily for 7-10 days is the standard dose. For varicella, the pediatric dose is 20 mg/kg (up to 800 mg) four times daily for 5 days, and the adult dose is 800 mg four times daily for 5 days. For pediatric patients, the dose for HSV infections is 10-20 mg/kg per dose (up to 400 mg) three to five times daily, depending on the indication. The oral suspension (200 mg/5 mL) is available for children and adults who have difficulty swallowing tablets. For patients with renal impairment, dose adjustment is essential to prevent drug accumulation and potential toxicity. The dosing interval should be extended based on the creatinine clearance. For patients with creatinine clearance of 25-50 mL/min, the recommended dose is given every 8 hours. For those with creatinine clearance of 10-25 mL/min, the dose is given every 12 hours. For those with creatinine clearance less than 10 mL/min, the dose is given every 24 hours, typically at half the usual dose. Patients undergoing hemodialysis should receive the dose after dialysis, as acyclovir is effectively removed by the procedure. For elderly patients, renal function should be assessed before initiating therapy, and the dose should be adjusted accordingly. Elderly patients are more susceptible to the neurotoxic effects of acyclovir, particularly at high doses, and dose reduction may be necessary even if the calculated creatinine clearance suggests standard dosing is appropriate. For patients with hepatic impairment, no dose adjustment is necessary, as acyclovir is not metabolized by the liver. Acivir Pills should be taken with a full glass of water, and patients should be advised to maintain adequate hydration throughout therapy to reduce the risk of crystal nephropathy. The tablets can be taken with or without food. Taking the medication with food may help reduce gastrointestinal side effects such as nausea. Adherence to the prescribed dosing schedule is critical for maintaining therapeutic drug concentrations. Because acyclovir has a short half-life and is eliminated rapidly, missing doses can lead to subtherapeutic levels and reduced efficacy. Patients should be counseled to take the medication exactly as prescribed and to set reminders if necessary to avoid missed doses. If a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next dose, in which case the missed dose should be skipped and the regular schedule resumed. The duration of therapy should be completed as prescribed, even if symptoms improve before the medication is finished. For suppressive therapy, the medication must be taken consistently every day to maintain protection against recurrent episodes. For episodic treatment of recurrent infections, the medication should be started at the first sign of a recurrence, ideally during the prodromal phase, and continued for the full prescribed duration. Patients should be advised to keep a supply of medication on hand so that treatment can be initiated promptly when needed. The specific dosing regimen should be prescribed by a healthcare provider based on the individual patient’s condition, medical history, and response to therapy. Self-medication with Acivir Pills for suspected herpes infections should be avoided unless the diagnosis has been confirmed by a healthcare provider, as other conditions may mimic herpes infections and require different treatment.
Side effects and adverse reactions
Acivir Pills are generally very well tolerated, with most adverse effects being mild to moderate in severity. The most commonly reported side effects with oral acyclovir therapy are gastrointestinal. Nausea occurs in approximately 5-10% of patients, particularly at higher doses such as those used for herpes zoster (800 mg five times daily). Vomiting, diarrhea, and abdominal pain occur less frequently. These symptoms are often transient and may be reduced by taking the medication with food. Headache is another common side effect, occurring in approximately 10-15% of patients. It is usually mild and may resolve with continued therapy or with the use of over-the-counter analgesics. Dizziness, fatigue, and malaise have been reported in a smaller proportion of patients. Dermatologic reactions, including rash, pruritus, and urticaria, occur rarely. Photosensitivity reactions have been reported, and patients should be advised to use sun protection during therapy. Alopecia (hair loss) has been reported in rare cases, typically with prolonged therapy. Neuropsychiatric effects are an important concern, particularly in elderly patients, those with renal impairment, and those receiving high doses. Confusion, hallucinations, agitation, somnolence, and delirium have been reported. These effects are more common with intravenous acyclovir but can occur with high-dose oral therapy in susceptible patients. Seizures, tremors, and myoclonus have been reported in severe cases. These neurotoxic effects are generally reversible upon dose reduction or discontinuation of the drug, but they require prompt medical attention. The mechanism of neurotoxicity is thought to involve accumulation of acyclovir and its metabolites in the central nervous system, particularly in patients with impaired renal function who cannot clear the drug efficiently. Renal effects are a significant concern, though they are more common with intravenous acyclovir than with oral therapy. Acyclovir can precipitate in the renal tubules, particularly when administered as a rapid intravenous infusion or in patients with dehydration or pre-existing renal impairment. This crystal nephropathy can present as acute kidney injury with flank pain, hematuria, and elevated serum creatinine. The risk can be minimized by ensuring adequate hydration, administering intravenous infusions slowly, and adjusting the dose for renal function. With oral therapy, renal toxicity is rare but can occur in patients with pre-existing renal impairment, those taking high doses, or those who are dehydrated. Hepatic effects are uncommon. Transient elevations in liver enzymes have been reported, but clinically significant hepatotoxicity is rare. Hematologic effects, including thrombocytopenia, leukopenia, and neutropenia, have been reported rarely, typically with prolonged high-dose therapy. Hypersensitivity reactions, including anaphylaxis, angioedema, and Stevens-Johnson syndrome, are extremely rare. Patients who experience signs of an allergic reaction, such as rash, hives, swelling of the face or throat, or difficulty breathing, should discontinue the medication and seek immediate medical attention. The long-term safety of acyclovir has been evaluated in clinical studies of patients receiving suppressive therapy for genital herpes for periods exceeding 10 years. These studies have demonstrated that acyclovir is safe for long-term use, with no evidence of cumulative toxicity, increased risk of cancer, or other adverse outcomes. The safety profile during pregnancy has been evaluated through pregnancy registries and observational studies involving thousands of exposed pregnancies, and no increased risk of birth defects or adverse pregnancy outcomes has been identified. Acyclovir is one of the few antiviral medications for which substantial safety data exist during pregnancy. Patients should be counseled about the common side effects and advised to report any persistent, severe, or concerning symptoms to their healthcare provider. The importance of adequate hydration should be emphasized, particularly for patients receiving high-dose therapy. With appropriate monitoring and dose adjustment for renal function, the risk of serious adverse effects is low, and the benefits of acyclovir therapy far outweigh the risks for most patients.
Drug interactions and contraindications
Acivir Pills have a relatively favorable drug interaction profile compared to many other medications, but several interactions warrant attention. The most significant pharmacokinetic interaction is with probenecid, which reduces the renal tubular secretion of acyclovir, leading to increased plasma concentrations and a prolonged half-life. While this interaction is not usually clinically significant for standard oral doses, it may increase the risk of toxicity in patients receiving high-dose therapy or those with pre-existing renal impairment. Close monitoring is advised if these drugs are used concurrently. The concomitant use of acyclovir with other nephrotoxic medications increases the risk of renal toxicity. Drugs that can potentiate the nephrotoxic effects of acyclovir include aminoglycoside antibiotics (gentamicin, tobramycin), cyclosporine, tacrolimus, amphotericin B, nonsteroidal anti-inflammatory drugs (particularly in high doses or in elderly or dehydrated patients), cisplatin, and methotrexate. When these combinations are necessary, renal function should be monitored closely, and appropriate dose adjustments should be made. The combination of acyclovir with drugs that affect the central nervous system may increase the risk of neurotoxicity. This is particularly relevant for elderly patients and those receiving high-dose acyclovir. Caution should be exercised when acyclovir is used concurrently with opioids, benzodiazepines, antipsychotics, tricyclic antidepressants, and other medications with central nervous system activity. Patients should be monitored for signs of excessive sedation, confusion, or other neurological symptoms. The interaction between acyclovir and theophylline has been reported in some studies, with acyclovir potentially increasing theophylline concentrations. However, the clinical significance of this interaction is unclear, and routine monitoring of theophylline levels is not required unless the patient develops symptoms of theophylline toxicity. Acyclovir may reduce the efficacy of live attenuated varicella vaccine and herpes zoster vaccine. These vaccines contain live, attenuated VZV, and acyclovir, by inhibiting VZV replication, may impair the immune response to the vaccine. The vaccines should be administered at least 24 hours before starting acyclovir therapy, or acyclovir should be discontinued for at least 24 hours before vaccine administration. Inactivated vaccines, such as the recombinant zoster vaccine, are not affected by acyclovir. Acyclovir does not interact with oral contraceptives, and it does not affect the efficacy of hormonal birth control. It also has no known interactions with alcohol, caffeine, or food. Patients can use acyclovir without dietary restrictions, though adequate hydration is recommended. Contraindications to Acivir Pills are few. The drug is contraindicated in patients with known hypersensitivity to acyclovir, valacyclovir, or any component of the formulation. Patients who have experienced an allergic reaction to acyclovir should not receive the drug. There are no other absolute contraindications, but several precautions must be observed. As previously discussed, dose adjustment for renal impairment is essential, and caution is required in elderly patients and those with pre-existing central nervous system disease. The use of acyclovir during pregnancy is not contraindicated, and the drug is commonly used for the treatment and suppression of genital herpes in pregnant women. The benefits of preventing HSV transmission to the neonate during delivery are considered to outweigh the theoretical risks of drug exposure. Acyclovir is classified as FDA Pregnancy Category B, indicating that animal studies have not demonstrated a risk to the fetus. Breastfeeding is not contraindicated during acyclovir therapy, though the drug is excreted into breast milk in small amounts. The concentration in breast milk is insufficient to cause adverse effects in the nursing infant, and the American Academy of Pediatrics considers acyclovir to be compatible with breastfeeding. In pediatric patients, acyclovir is used and is considered safe when dosed appropriately based on weight. In elderly patients, dose adjustment based on renal function is the primary consideration, and these patients should be monitored closely for neurotoxic effects. The favorable interaction profile and limited contraindications of acyclovir make it a versatile and widely used antiviral medication. However, healthcare providers should always conduct a thorough medical and medication history before prescribing acyclovir, with particular attention to renal function, concurrent use of nephrotoxic medications, and any history of hypersensitivity reactions.
Special populations
In pediatric patients, Acivir Pills are used for the treatment of varicella (chickenpox), orolabial herpes, and, in adolescents, genital herpes. The safety and efficacy of acyclovir in children have been established through clinical trials and extensive clinical experience. The dose for children is calculated based on body weight, with a maximum dose equivalent to the adult dose. The oral suspension formulation (200 mg/5 mL or 400 mg/5 mL) facilitates accurate dosing in young children. For neonatal herpes simplex infections, intravenous acyclovir is the standard of care, and oral therapy is used only for suppressive therapy following intravenous treatment. In elderly patients, acyclovir is commonly used for the treatment of herpes zoster, which occurs with increased frequency and severity in this population. Age-related decline in renal function is the primary consideration affecting dosing. Creatinine clearance should be estimated using a validated equation, and the dose should be adjusted accordingly. Elderly patients are more susceptible to the neurotoxic effects of acyclovir, including confusion, hallucinations, and somnolence, even when the dose is appropriately adjusted for renal function. Close monitoring for neurological symptoms is recommended, and patients should be advised to report any changes in mental status to their healthcare provider. Adequate hydration is particularly important in elderly patients to maintain renal function and reduce the risk of crystal nephropathy. In pregnant patients, acyclovir is used for the treatment of first-episode and recurrent genital herpes, and for suppressive therapy beginning at 36 weeks of gestation to reduce the risk of HSV transmission to the neonate during delivery. The safety of acyclovir during pregnancy has been studied. The Acyclovir Pregnancy Registry, which monitored exposures from 1984 through 1999, found no increased risk of birth defects among infants exposed to acyclovir during the first trimester compared to the general population. Subsequent observational studies have confirmed these findings. Acyclovir is the antiviral agent of choice for the management of genital herpes during pregnancy. The recommended dose for suppressive therapy during the third trimester is 400 mg twice daily. Intravenous acyclovir is used for the treatment of severe HSV or VZV infections during pregnancy, such as disseminated HSV or varicella pneumonia. In breastfeeding women, acyclovir is excreted into breast milk in small amounts, with the infant receiving approximately 1-2% of the maternal dose. This amount is well below the therapeutic dose for infants and is not expected to cause adverse effects. The American Academy of Pediatrics classifies acyclovir as compatible with breastfeeding. Women who are breastfeeding and require acyclovir therapy should be reassured about its safety. In immunocompromised patients, herpesvirus infections can be more severe, more prolonged, and more prone to recurrence than in immunocompetent individuals. Patients with HIV infection, those receiving chemotherapy for cancer, and those who have undergone organ transplantation are at particular risk. These patients may require higher doses of acyclovir, longer treatment durations, and suppressive therapy to prevent recurrences. Intravenous acyclovir is often required for initial treatment of severe infections in immunocompromised patients, followed by oral therapy for consolidation and suppression. Resistance to acyclovir is more common in immunocompromised patients, particularly those with advanced HIV infection or those who have received prolonged or repeated courses of therapy. If a patient fails to respond to acyclovir therapy, resistance should be suspected, and alternative antiviral agents such as foscarnet or cidofovir should be considered. In patients with renal impairment, dose adjustment is mandatory, as discussed in the dosage section. The dose and dosing interval should be based on the calculated creatinine clearance. Patients with severe renal impairment (creatinine clearance less than 10 mL/min) should receive acyclovir at extended intervals, and those undergoing hemodialysis should receive the dose after dialysis. In patients with hepatic impairment, no dose adjustment is necessary, as acyclovir is not metabolized by the liver. However, patients with severe hepatic impairment should be monitored for adverse effects as a precaution. In patients with a history of neurological conditions, including epilepsy, dementia, or cerebrovascular disease, acyclovir should be used with caution, as these patients may be at increased risk for neurotoxic effects. The management of acyclovir therapy in these special populations requires a personalized approach that considers the unique pharmacokinetic, safety, and efficacy considerations relevant to each group.
Resistance and management
Resistance to acyclovir is an important clinical consideration, particularly in immunocompromised patients who require prolonged or repeated courses of therapy. The prevalence of acyclovir resistance in immunocompetent patients is low, generally estimated at less than 1% for HSV isolates. In immunocompromised populations, the prevalence is higher, ranging from 3-10% for HSV and up to 5% for VZV, depending on the specific patient population, the duration of acyclovir exposure, and the level of immunosuppression. The mechanisms of acyclovir resistance involve mutations in the viral genes encoding thymidine kinase (TK) or DNA polymerase. The most common mechanism, accounting for approximately 95% of resistant HSV isolates, involves mutations in the TK gene that result in reduced or absent TK activity. Because TK is required for the initial phosphorylation of acyclovir, a mutant virus with deficient TK activity cannot activate the drug, and acyclovir remains in its inactive form. TK mutations can be classified into three types: TK-negative mutants, which produce no functional TK; TK-altered mutants, which produce a TK enzyme with reduced affinity for acyclovir; and TK-partial mutants, which produce a reduced amount of functional TK. TK-negative mutants are the most common and are highly resistant to acyclovir and to other drugs that require TK activation, including valacyclovir, penciclovir, and famciclovir. The second mechanism of resistance, accounting for approximately 5% of resistant isolates, involves mutations in the viral DNA polymerase gene. These mutations alter the structure of the DNA polymerase so that it has reduced affinity for acyclovir triphosphate, allowing viral DNA replication to proceed in the presence of the drug. DNA polymerase mutants may exhibit cross-resistance to other antiviral agents that target the viral DNA polymerase, including ganciclovir, penciclovir, and foscarnet, though the extent of cross-resistance varies depending on the specific mutation. The clinical presentation of acyclovir-resistant HSV infection typically involves persistent, non-healing mucocutaneous ulcers that fail to respond to standard doses of acyclovir. These lesions can be painful, disfiguring, and may serve as a portal for secondary bacterial infections. In severe cases, particularly in profoundly immunocompromised patients, disseminated HSV infection can occur, with involvement of the esophagus, lungs, and other internal organs. The diagnosis of acyclovir resistance should be suspected in any patient who fails to respond to appropriate doses of acyclovir within 7-10 days, particularly if the patient is immunocompromised. Confirmation of resistance requires viral culture and antiviral susceptibility testing, which may not be readily available in all clinical settings. In the absence of susceptibility testing, the clinical response to therapy is often used as a surrogate marker for resistance. The management of acyclovir-resistant HSV infections involves several strategies. The first-line alternative agent for acyclovir-resistant HSV is foscarnet, a viral DNA polymerase inhibitor that does not require TK activation. Foscarnet is administered intravenously at a dose of 40-60 mg/kg every 8 hours, adjusted for renal function. It is effective against most acyclovir-resistant HSV isolates, including TK-negative mutants. However, foscarnet is associated with significant toxicity, including nephrotoxicity, electrolyte disturbances (particularly hypocalcemia, hypomagnesemia, and hypokalemia), and genital ulcerations. Patients receiving foscarnet require close monitoring of renal function and electrolytes, and adequate hydration. The second-line alternative is cidofovir, a nucleotide analogue that also does not require TK activation. Cidofovir is administered intravenously at a dose of 5 mg/kg once weekly, with probenecid to reduce nephrotoxicity. The topical formulation of cidofovir (1% gel or 3% cream) may be used for mucocutaneous lesions, though availability is limited. Cidofovir is associated with significant nephrotoxicity, which may be partially mitigated by probenecid and aggressive hydration. Imiquimod, an immune response modifier, has been used as an alternative or adjunctive therapy in some cases, though data supporting its efficacy are limited. For acyclovir-resistant VZV infections, foscarnet is the preferred agent, with the same dosing and monitoring considerations as for HSV. Cidofovir is an alternative for resistant VZV infections. The prevention of acyclovir resistance is an important goal of antiviral stewardship. Strategies to minimize the emergence of resistance include using appropriate doses of acyclovir (avoiding subtherapeutic dosing), ensuring adherence to the prescribed regimen, avoiding unnecessary or prolonged courses of therapy, and considering the use of suppressive therapy in patients with frequent recurrences to reduce the total number of treatment episodes. In immunocompromised patients, the judicious use of acyclovir and periodic reassessment of the need for continued therapy are important. The development of new antiviral agents with activity against acyclovir-resistant viruses remains an active area of research, with promising agents in development.
Frequently asked questions
Patients commonly ask about how quickly these medications work, their safety profiles, and proper usage. Most symptoms improve within days of starting treatment, but completing the full prescribed course is essential for preventing recurrence. These medications should only be used under appropriate medical guidance. Common concerns include drug interactions, side effects, and use during pregnancy or breastfeeding. Patients are advised to discuss their specific medical history with a healthcare provider before starting any new medication and to report any persistent or unusual symptoms promptly. Generic versions of these medications offer the same therapeutic benefits as brand-name products at a lower cost.